Literature DB >> 19901966

Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.

M K El-Tanani1, D Jin, F C Campbell, P G Johnston.   

Abstract

Osteopontin is a secreted, integrin-binding and phosphorylated acidic glycoprotein, which has an important role in tumour progression. We have shown that Wnt, Ets, AP-1, c-jun and beta-catenin/Lef-1/Tcf-1 stimulates OPN transcription in rat mammary carcinoma cells by binding to a specific promoter sequence. However, co-repressors of OPN have not been identified. In this study, we have used the bacterial two-hybrid system to isolate cDNA-encoding proteins that bind to OPN and modulate its role in malignant transformation. Using this approach we isolated interferon-induced transmembrane protein 3 gene (IFITM3) as a potential protein partner. We show that IFITM3 and OPN interact in vitro and in vivo and that IFITM3 reduces osteopontin (OPN) mRNA expression, possibly by affecting OPN mRNA stability. Stable transfection of IFITM3 inhibits OPN, which mediates anchorage-independent growth, cell adhesion and cell invasion. Northern blot analysis revealed an inverse mRNA expression pattern of IFITM3 and OPN in human mammary cell lines. Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well. We also identified an IFITM3 DNA-binding domain, which interacts with OPN, deletion of which abolished its inhibitive effect on OPN. This work has shown for the first time that IFITM3 physically interacts with OPN and reduces OPN mRNA expression, which mediates cell adhesion, cell invasion, colony formation in soft agar and metastasis in a rat model system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901966     DOI: 10.1038/onc.2009.379

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases.

Authors:  D J Mole; C O'Neill; P Hamilton; B Olabi; V Robinson; L Williams; T Diamond; M El-Tanani; F C Campbell
Journal:  Br J Cancer       Date:  2011-02-22       Impact factor: 7.640

Review 3.  More than meets the I: the diverse antiviral and cellular functions of interferon-induced transmembrane proteins.

Authors:  Guoli Shi; Olivier Schwartz; Alex A Compton
Journal:  Retrovirology       Date:  2017-11-21       Impact factor: 4.602

4.  Interferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma.

Authors:  Dong Zhang; Huimin Wang; Huijie He; Haiying Niu; Yu Li
Journal:  Thorac Cancer       Date:  2017-05-23       Impact factor: 3.500

5.  A Bayesian Approach for Analysis of Whole-Genome Bisulfite Sequencing Data Identifies Disease-Associated Changes in DNA Methylation.

Authors:  Owen J L Rackham; Sarah R Langley; Thomas Oates; Eleni Vradi; Nathan Harmston; Prashant K Srivastava; Jacques Behmoaras; Petros Dellaportas; Leonardo Bottolo; Enrico Petretto
Journal:  Genetics       Date:  2017-02-17       Impact factor: 4.562

6.  The role of IFITM3 in the growth and migration of human glioma cells.

Authors:  Bing Zhao; Hongliang Wang; Gang Zong; Ping Li
Journal:  BMC Neurol       Date:  2013-12-27       Impact factor: 2.474

7.  Overexpression of IFITM3 predicts the high risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Yang Jia; Miao Zhang; Wenpeng Jiang; Zhiping Zhang; Shiting Huang; Zhou Wang
Journal:  PeerJ       Date:  2015-10-29       Impact factor: 2.984

Review 8.  Malignancy and IFITM3: Friend or Foe?

Authors:  Ushani S Rajapaksa; Chen Jin; Tao Dong
Journal:  Front Oncol       Date:  2020-12-08       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.